9/26 We have been commissioned by Chase Therapeutics to conduct research on the diagnosis of Parkinson's disease.

We have entered into a research agreement with Chase Therapeutics (Washington D.C., USA), a startup focused on drug discovery, to develop diagnostic biomarkers for Parkinson's disease.

BioPhenoMA、Chase Therapeutics社からパーキンソン病診断の委託研究を受注 | 株式会社BioPhenoMAのプレスリリース (prtimes.jp)